Status:
UNKNOWN
Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Lead Sponsor:
Seoul National University Hospital
Conditions:
Remimazolam
Anesthesia, General
Eligibility:
All Genders
19+ years
Brief Summary
The aim of this study is to compare the bispectral index (BIS) and patient state index (PSI) during general anesthesia using remimazolam. The infusion rate of remimazolam is 6-12mg/kg/h during inducti...
Eligibility Criteria
Inclusion
- Patients ≥ 19 years need general anesthesia
- American Society of Anesthesiologists (ASA) Classification I, II
- Written informed consent
Exclusion
- American Society of Anesthesiologists (ASA) Classification III, IV, V
- BMI \> 40kg/m\^2
- Past medical history of anaphylactic reaction to remimazolam, remifentanil, or other benzodiazepines.
- Administration of anxiolytics, antipsychotics, rifampicin, succinylcholine, neostigmine, flumazenil, and cyclosporin within the past 24 hours
- Benzodiazepine user (e.g. for seizure control)
- Transfer to intensive care unit after surgery
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05432050
Start Date
July 1 2022
End Date
December 31 2023
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080